New Delhi, July 15 -- The initial public offering of Bengaluru-based Anthem Biosciences, a contract research and innovation provider, has thrown the spotlight on India's Contract Development and Manufacturing Organization (CDMO) space.

contract drug manufacturing

On Day 1, the IPO was subscribed 0.7x overall. Among non-institutional investors, bids above Rs.10 lakh were subscribed 1.37x, and those between Rs.2 lakh and Rs.10 lakh saw nearly 2x subscription, NSE data showed.

In the grey market, Anthem shares were quoting at Rs.679-about 19% above the issue price, according to IPO data platform Investor Gain.

The excitement isn't limited to Anthem. Shares of CDMO players have been surging. From July 2023 to mid-July 2024, Divi's Laborat...